Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis

Maulana Azad Medical College

Status: Completed

Conditions: Pulmonary Tuberculosis

Treatments: Drug: ATT

Study type: Observational

Funder types: Other

Identifiers

NCT00834353

F.501(134)/02-EC/MC(Aca)/16713

Details and patient eligibility

About

N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is metabolized by CYP2E1 to a toxic metabolite. Slow acetylator genotype of NAT2 and wild type genotype of CYP2E1 gene has been attributed to greater toxicity of ATT drug. Therefore this study has been designed to analyze the genetic polymorphism of NAT2 and CYP2E1 genes in tuberculosis patients who developed drug induced hepatitis upon administration of antituberculosis drug.Polymorphism study of NAT2 and CYP2E1 gene may help in predicting the high risk group of ATT induced hepatitis.

Sex: All

Ages: 10 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with pulmonary tuberculosis
• Patients receiving conventional antituberculosis drugs
• Patients who directly presented with antituberculosis drug induced hepatitis

Exclusion criteria

• Habitual alcohol drinkers
• Patients with evidence of viral hepatitis

Trial design

0 participants in 1 patient group

Pulmonary tuberculosis patients

Description:

Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs

Treatment:

Drug: ATT